| Sample | Title | Value | Rank |
|---|
| GSM1256968 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 1 | 419.833 | 91 |
| GSM1256969 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 2 | 494.02 | 93 |
| GSM1256970 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 3 | 704.93 | 95 |
| GSM1256971 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 4 | 1526.7 | 97 |
| GSM1256988 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 55 before YFV | 496.361 | 93 |
| GSM1256991 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 55 seven days after YFV | 446.179 | 92 |
| GSM1256989 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 56 before YFV | 670.655 | 95 |
| GSM1256992 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 56 seven days after YFV | 605.95 | 94 |
| GSM1256990 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 57 before YFV | 589.593 | 94 |
| GSM1256993 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 57 seven days after YFV | 725.131 | 95 |